Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74->Val or Ile and Val-75->Leu or Ile) HIV-1 mutants

被引:83
作者
Kleim, JP
Rosner, M
Winkler, I
Paessens, A
Kirsch, R
Hsiou, Y
Arnold, E
Riess, G
机构
[1] BAYER AG,PHARMA RES CTR,D-42096 WUPPERTAL,GERMANY
[2] RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854
[3] RUTGERS STATE UNIV,DEPT CHEM,PISCATAWAY,NJ 08854
关键词
D O I
10.1073/pnas.93.1.34
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The quinoxaline nonnucleoside RT inhibitor (NNRTI) (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl) 3,4-dihydroquinoxaline-2(1H)-thione (HBY 097) was used to select for drug-resistant HIV-1 variants in vitro, The viruses first developed mutations affecting the NNRTI-binding pocket, and five of six strains displayed the RT G190-->E substitution, which is characteristic for HIV-1 resistance against quinoxalines. In one variant, a new mutant (G190-->Q) most likely evolved from preexisting G190-->E mutants, The negative charge introduced by the G190-->E substitution was maintained at that site of the pocket by simultaneous selection for V179-->D together with G190-->Q. After continued exposure to the drug, mutations at positions so far known to be specific for resistance against nucleoside RT inhibitors (NRTIs) (L74-->V/I and V75-->L/I) were consistently detected in all cultures, The inhibitory activities of the cellular conversion product of 2',3'-dideoxyinosine (ddI, didanosine), 2',3'-dideoxyadenosine (ddA) and of 2',3'-didehydro-3'-deoxythymidine (d4T, stavudine) against these late-passage viruses were shown to be enhanced with the L74-->V/I RT mutant virus as compared with the wild-type (wt) HIV-1(MN) isolate, Clonal analysis proved linkage of the codon 74 and codon 75 mutations to the NNRTI-specific mutations in all RT gene fragments, The nonnucleoside- and nucleoside-resistance mutation sites are separated by approximately 35 Angstrom. We propose that the two sites ''communicate'' through the template-primer which is situated in the DNA-binding cleft between these two sites, Quinoxalines cause high selective pressure on HIV-1 replication in vitro; however, the implication of these findings for the treatment of HIV-1 infection has yet to be determined.
引用
收藏
页码:34 / 38
页数:5
相关论文
共 28 条
[1]   ANALYSIS OF A RAPE CASE BY DIRECT SEQUENCING OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 POL AND GAG GENES [J].
ALBERT, J ;
WAHLBERG, J ;
LEITNER, T ;
ESCANILLA, D ;
UHLEN, M .
JOURNAL OF VIROLOGY, 1994, 68 (09) :5918-5924
[2]   TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-INFECTED CELLS WITH COMBINATIONS OF HIV-1-SPECIFIC INHIBITORS RESULTS IN A DIFFERENT RESISTANCE PATTERN THAN DOES TREATMENT WITH SINGLE-DRUG THERAPY [J].
BALZARINI, J ;
KARLSSON, A ;
PEREZPEREZ, MJ ;
CAMARASA, MJ ;
TARPLEY, WG ;
DECLERCQ, E .
JOURNAL OF VIROLOGY, 1993, 67 (09) :5353-5359
[3]   HIV-1-SPECIFIC REVERSE-TRANSCRIPTASE INHIBITORS SHOW DIFFERENTIAL ACTIVITY AGAINST HIV-1 MUTANT STRAINS CONTAINING DIFFERENT AMINO-ACID SUBSTITUTIONS IN THE REVERSE-TRANSCRIPTASE [J].
BALZARINI, J ;
KARLSSON, A ;
PEREZPEREZ, MJ ;
VRANG, L ;
WALBERS, J ;
ZHANG, H ;
OBERG, B ;
VANDAMME, AM ;
CAMARASA, MJ ;
DECLERCQ, E .
VIROLOGY, 1993, 192 (01) :246-253
[4]   RESISTANCE PATTERN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE TO QUINOXALINE S-2720 [J].
BALZARINI, J ;
KARLSSON, A ;
MEICHSNER, C ;
PAESSENS, A ;
RIESS, G ;
DECLERCQ, E ;
KLEIM, JP .
JOURNAL OF VIROLOGY, 1994, 68 (12) :7986-7992
[5]   MUTATIONAL ANALYSIS OF THE FINGERS AND PALM SUBDOMAINS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) REVERSE-TRANSCRIPTASE [J].
BOYER, PL ;
FERRIS, AL ;
CLARK, P ;
WHITMER, J ;
FRANK, P ;
TANTILLO, C ;
ARNOLD, E ;
HUGHES, SH .
JOURNAL OF MOLECULAR BIOLOGY, 1994, 243 (03) :472-483
[6]   SENSITIVITY OF WILD-TYPE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE TO DIDEOXYNUCLEOTIDES DEPENDS ON TEMPLATE LENGTH - THE SENSITIVITY OF DRUG-RESISTANT MUTANTS DOES NOT [J].
BOYER, PL ;
TANTILLO, C ;
JACOBOMOLINA, A ;
NANNI, RG ;
DING, JP ;
ARNOLD, E ;
HUGHES, SH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (11) :4882-4886
[7]   COMPREHENSIVE MUTANT ENZYME AND VIRAL VARIANT ASSESSMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE RESISTANCE TO NONNUCLEOSIDE INHIBITORS [J].
BYRNES, VW ;
SARDANA, VV ;
SCHLEIF, WA ;
CONDRA, JH ;
WATERBURY, JA ;
WOLFGANG, JA ;
LONG, WJ ;
SCHNEIDER, CL ;
SCHLABACH, AJ ;
WOLANSKI, BS ;
GRAHAM, DJ ;
GOTLIB, L ;
RHODES, A ;
TITUS, DL ;
ROTH, E ;
BLAHY, OM ;
QUINTERO, JC ;
STASZEWSKI, S ;
EMINI, EA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (08) :1576-1579
[8]   MUTATIONAL SENSITIVITY PATTERNS DEFINE CRITICAL RESIDUES IN THE PALM SUBDOMAIN OF THE REVERSE-TRANSCRIPTASE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
CHAO, SF ;
CHAN, VL ;
JURANKA, P ;
KAPLAN, AH ;
SWANSTROM, R ;
HUTCHISON, CA .
NUCLEIC ACIDS RESEARCH, 1995, 23 (05) :803-810
[9]   STRUCTURE OF HIV-1 REVERSE-TRANSCRIPTASE IN A COMPLEX WITH THE NONNUCLEOSIDE INHIBITOR ALPHA-APA-R-95845 AT 2.8-ANGSTROM RESOLUTION [J].
DING, J ;
DAS, K ;
TANTILLO, C ;
ZHANG, W ;
CLARK, AD ;
JESSEN, S ;
LU, X ;
HSIOU, Y ;
JACOBOMOLINA, A ;
ANDRIES, K ;
PAUWELS, R ;
MOEREELS, H ;
KOYMANS, L ;
JANSSEN, PAJ ;
SMITH, RH ;
KOEPKE, MK ;
MICHEJDA, CJ ;
HUGHES, SH ;
ARNOLD, E .
STRUCTURE, 1995, 3 (04) :365-379
[10]   A MUTATION IN REVERSE-TRANSCRIPTASE OF BIS(HETEROARYL)PIPERAZINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 THAT CONFERS INCREASED SENSITIVITY TO OTHER NONNUCLEOSIDE INHIBITORS [J].
DUEWEKE, TJ ;
PUSHKARSKAYA, T ;
POPPE, SM ;
SWANEY, SM ;
ZHAO, JQ ;
CHEN, ISY ;
STEVENSON, M ;
TARPLEY, WG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (10) :4713-4717